Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Many Bright Ideas TechnologiesMBGNF Return-on-Tangible-Asset is -600.00% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 213 Medical Diagnostics & Research companies, Many Bright Ideas Technologies ranks worse than 99.53% on this metric.
The historical rank and industry rank for Many Bright Ideas Technologies's Return-on-Tangible-Asset or its related term are showing as below:
MBGNF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -2960 Med: -1176.17 Max: 63.27
Current: -620
During the past 13 years, Many Bright Ideas Technologies's highest Return-on-Tangible-Asset was 63.27%. The lowest was -2960.00%. And the median was -1176.17%.
MBGNF's Return-on-Tangible-Asset is ranked worse than 99.53% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.4
vs MBGNF: -620.00
Many Bright Ideas Technologies (OTCPK:MBGNF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Many Bright Ideas Technologies Return-on-Tangible-Asset Related Terms
Many Bright Ideas Technologies Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Many Bright Ideas Technologies Return-on-Tangible-Asset Chart
MBGNF vs TMO, DHR, IDXX: Return-on-Tangible-Asset Comparison
For the Diagnostics & Research subindustry, Many Bright Ideas Technologies's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Many Bright Ideas Technologies Return-on-Tangible-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Many Bright Ideas Technologies's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Many Bright Ideas Technologies's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -600.00% mean?
Many Bright Ideas Technologies (MBGNF) has a Return-on-Tangible-Asset of -600.00% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Many Bright Ideas Technologies and its competitors. According to the industry distribution chart, Many Bright Ideas Technologies ranks #212 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 99.5%.
Is Many Bright Ideas Technologies' Return-on-Tangible-Asset too high?
Many Bright Ideas Technologies' current Return-on-Tangible-Asset is -600.00%. Based on the distribution chart, Many Bright Ideas Technologies ranks #212 out of 213 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Many Bright Ideas Technologies' Return-on-Tangible-Asset compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Many Bright Ideas Technologies ranks #212 out of 213 companies for Return-on-Tangible-Asset. This places Many Bright Ideas Technologies in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Asset depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Many Bright Ideas Technologies and its competitors. Many Bright Ideas Technologies's current Return-on-Tangible-Asset is -600.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Many Bright Ideas Technologies stock overvalued right now?
Many Bright Ideas Technologies (MBGNF) has a current Return-on-Tangible-Asset of -600.00%. The current Return-on-Tangible-Asset is -600.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Many Bright Ideas Technologies (MBGNF), the current Return-on-Tangible-Asset is -600.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Many Bright Ideas Technologies Business Description
Many Bright Ideas Technologies Inc is a Canada-based life science company. It focused on the development and commercialization of genomic-based clinical laboratory diagnostic tests. The company is engaged in managing the license and rights to GeneFx Lung, which is a proprietary gene expression-based test for identifying those patients with early-stage non-small-cell lung cancer.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBGNF has been successfully added to your 
